Metachronous hormonal syndromes in patients with pancreatic neuroendocrine tumors : A case-series study

Annals of Internal Medicine

Volumn 162, Issue 10, 2015, Pages 682-689

  De Mestier, Louis ^a   Hentic, Olivia ^b   Cros, Jérôme ^b   Walter, Thomas ^c   Roquin, Guillaume ^d   Brixi, Hedia ^a   Lombard Bohas, Catherine ^c   Hammel, Pascal ^b   Diebold, Marie Danièle ^a   Couvelard, Anne ^e   Ruszniewski, Philippe ^b   Cadiot, Guillaume ^a  

^a SERVICE DE DERMATOLOGIE   (France)

^b BEAUJON HOSPITAL   (France)

^c EDOUARD HERRIOT HOSPITAL   (France)

^d ANGERS UNIVERSITY HOSPITAL   (France)

^e BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GASTRIN; GLUCAGON; INSULIN; SOMATOSTATIN RECEPTOR; VASOACTIVE INTESTINAL POLYPEPTIDE; HORMONE; KI 67 ANTIGEN; TUMOR MARKER;

ADULT; AGED; ANTIBODY LABELING; ARTICLE; CANCER GROWTH; CASE STUDY; CONTROLLED STUDY; ENDOCRINE DISEASE; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; METACHRONOUS HORMONAL SYNDROME; PANCREATIC NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCINTIGRAPHY; TUMOR BIOPSY; TUMOR DIAGNOSIS; CLINICAL TRIAL; DISEASE COURSE; MIDDLE AGED; MULTICENTER STUDY; PANCREAS TUMOR; PATHOLOGY; SECRETION (PROCESS); SYNDROME;

ADULT; AGED; DISEASE PROGRESSION; FEMALE; GASTRINS; GLUCAGON; HORMONES; HUMANS; INSULIN; KI-67 ANTIGEN; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; RETROSPECTIVE STUDIES; SYNDROME; TUMOR MARKERS, BIOLOGICAL; VASOACTIVE INTESTINAL PEPTIDE;

EID: 84937512397     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/M14-2132     Document Type: Article

References (25)

1. Lepage C, Bouvier AM, Faivre J. Endocrine tumours: Epidemiology of malignant digestive neuroendocrine tumours. Eur J Endocrinol. 2013;168:77-83. [PMID: 23349330] doi:10.1530/EJE-12-0418.
2. Rindi G, Arnold R, Bosman FT. Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In: Bosman FT, Carneiro F, Hruban RH, Theise ND, eds. WHO Classification of Tumours of the Digestive System. 4th ed. Lyon, France: International Agency for Research on Cancer; 2010:13-4.
3. Falconi M, Bartsch DK, Eriksson B, Klöppel G, Lopes JM, O'Connor JM, et al; Barcelona Consensus Conference participants. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: Welldifferentiated pancreatic non-functioning tumors. Neuroendocrinology. 2012;95:120-34. [PMID: 22261872] doi:10.1159/000335587.
4. Lombard-Bohas C, Mitry E, O'Toole D, Louvet C, Pillon D, Cadiot G, et al; FFCD-ANGH-GERCOR. Thirteen-month registration of patients with gastroenteropancreatic endocrine tumours in France. Neuroendocrinology. 2009;89:217-22. [PMID: 18719344] doi:10.1159/000151562.
5. Kulke MH, Anthony LB, Bushnell DL, de Herder, WW, Goldsmith SJ, Klimstra DS, et al; North American Neuroendocrine Tumor Society (NANETS). NANETS treatment guidelines: Well-differentiated neuroendocrinetumorsof thestomachandpancreas. Pancreas.2010; 39:735-52.[PMID:20664472]doi:10.1097/MPA.0b013e3181ebb168.
6. Jensen RT, Cadiot G, Brandi ML, de Herder WW, Kaltsas G, Komminoth P, et al; Barcelona Consensus Conference participants. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology. 2012;95:98-119. [PMID: 22261919] doi:10.1159/000335591.
7. Lind SE, Weitzman SA. The insidious development of symptomatic secondary hormone syndromes in patients with malignant endocrine tumors. Am J Med Sci. 1985;290:107-10. [PMID: 2996349].
8. Wynick D, Williams SJ, Bloom SR. Symptomatic secondary hormone syndromes in patients with established malignant pancreatic endocrine tumors. N Engl J Med. 1988;319:605-7. [PMID: 2842676].
9. Mizuno N, Naruse S, Kitagawa M, Ishiguro H, Ito O, Ko SB, et al. Insulinoma with subsequent association of Zollinger-Ellison syndrome. Intern Med. 2001;40:386-90. [PMID: 11393407].
10. Rustagi T, Siegel RD. Zollinger-Ellison syndrome with subsequent association of insulinoma [Letter]. JOP. 2010;11:486-8. [PMID: 20818125].
11. Vashi PG, Gupta D, Dahlk S. A unique case of a nonfunctional metastatic pancreatic neuroendocrine tumor transforming into an insulin-secreting tumor with an unusual clinical course [Letter]. Pancreas. 2011;40:781-4. [PMID: 21673539] doi:10.1097/MPA.0b013e318212c42d.
12. Sobin LH, Gospodarowicz MK, Wittekind C, eds; International Union Against Cancer. TNM Classification of Malignant Tumours. 7th ed. Chichester, UK: Wiley-Blackwell; 2009.
13. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-47. [PMID: 19097774] doi:10.1016/j.ejca.2008.10.026.
14. Halfdanarson TR, Rubin J, Farnell MB, Grant CS, Petersen GM. Pancreatic endocrine neoplasms: Epidemiology and prognosis of pancreatic endocrine tumors. Endocr Relat Cancer. 2008;15:409-27. [PMID: 18508996] doi:10.1677/ERC-07-0221.
15. Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology. 2008;135:1469-92. [PMID: 18703061] doi:10.1053/j.gastro.2008.05.047.
16. Chiang HC, O'Dorisio TM, Huang SC, Maton PN, Gardner JD, Jensen RT. Multiple hormone elevations in Zollinger-Ellison syndrome. Prospective study of clinical significance and of the development of a second symptomatic pancreatic endocrine tumor syndrome. Gastroenterology. 1990;99:1565-75. [PMID: 2227272].
17. Vinik AI, Woltering EA, Warner RR, Caplin M, O'Dorisio TM, Wiseman GA, et al; North American Neuroendocrine Tumor Society (NANETS). NANETS consensus guidelines for the diagnosis of neuroendocrine tumor. Pancreas. 2010;39:713-34. [PMID: 20664471] doi:10.1097/MPA.0b013e3181ebaffd.
18. Crona J, Eriksson B, Welin S. Secondary hormonal syndromes in patients with sporadic neuroendocrine tumors [Abstract]. Presented at 11th Annual European Neuroendocrine Tumor Society Conference, Barcelona, Spain, 5-7 March 2014. Abstract no. F4.
19. Bilimoria KY, Talamonti MS, Tomlinson JS, Stewart AK, Winchester DP, Ko CY, et al. Prognostic score predicting survival after resection of pancreatic neuroendocrine tumors: Analysis of 3851 patients. Ann Surg. 2008;247:490-500. [PMID: 18376195] doi:10.1097/SLA.0b013e31815b9cae.
20. Couvelard A, Deschamps L, Ravaud P, Baron G, Sauvanet A, Hentic O, et al. Heterogeneity of tumor prognostic markers: A reproducibility study applied to liver metastases of pancreatic endocrine tumors. Mod Pathol. 2009;22:273-81. [PMID: 18997736] doi:10.1038/modpathol.2008.177.
21. Zen Y, Heaton N. Elevated Ki-67 labeling index in 'synchronous liver metastases' of well differentiated enteropancreatic neuroendocrine tumor. Pathol Int. 2013;63:532-8. [PMID: 24274715] doi:10.1111/pin.12108.
22. Miller HC, Drymousis P, Flora R, Goldin R, Spalding D, Frilling A. Role of Ki-67 proliferation index in the assessment of patients with neuroendocrine neoplasias regarding the stage of disease. World J Surg. 2014;38:1353-61. [PMID: 24493070] doi:10.1007/s00268-014-2451-0.
23. Singh S, Hallet J, Rowsell C, Law CH. Variability of Ki-67 labeling index in multiple neuroendocrine tumors specimens over the course of the disease. Eur J Surg Oncol. 2014;40:1517-22. [PMID: 25088936] doi:10.1016/j.ejso.2014.06.016.
24. Aparicio S, Caldas C. The implications of clonal genome evolution for cancer medicine. N Engl J Med. 2013;368:842-51. [PMID: 23445095] doi:10.1056/NEJMra1204892.
25. Yates LR, Campbell PJ. Evolution of the cancer genome. Nat Rev Genet. 2012;13:795-806. [PMID: 23044827] doi:10.1038/nrg3317.